2.86
price down icon11.18%   -0.36
after-market Dopo l'orario di chiusura: 2.94 0.08 +2.80%
loading
Precedente Chiudi:
$3.22
Aprire:
$3.19
Volume 24 ore:
1.96M
Relative Volume:
2.14
Capitalizzazione di mercato:
$586.95M
Reddito:
-
Utile/perdita netta:
$-54.70M
Rapporto P/E:
-8.6667
EPS:
-0.33
Flusso di cassa netto:
$-51.36M
1 W Prestazione:
-15.88%
1M Prestazione:
+4.38%
6M Prestazione:
-27.96%
1 anno Prestazione:
-43.59%
Intervallo 1D:
Value
$2.85
$3.33
Intervallo di 1 settimana:
Value
$2.805
$3.558
Portata 52W:
Value
$2.31
$5.11

Savara Inc Stock (SVRA) Company Profile

Name
Nome
Savara Inc
Name
Telefono
51285113796
Name
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Name
Dipendente
59
Name
Cinguettio
@SavaraPharma
Name
Prossima data di guadagno
2025-03-26
Name
Ultimi documenti SEC
Name
SVRA's Discussions on Twitter

Confronta SVRA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SVRA
Savara Inc
2.86 586.95M 0 -54.70M -51.36M -0.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Savara Inc Stock (SVRA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-20 Iniziato Wells Fargo Overweight
2024-11-13 Downgrade Evercore ISI Outperform → In-line
2024-02-15 Iniziato JMP Securities Mkt Outperform
2023-11-07 Iniziato Guggenheim Buy
2023-05-16 Aggiornamento Jefferies Hold → Buy
2023-03-31 Downgrade Jefferies Buy → Hold
2021-03-16 Iniziato Piper Sandler Overweight
2021-03-15 Iniziato Oppenheimer Outperform
2019-06-13 Reiterato H.C. Wainwright Buy
2019-06-13 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2019-06-13 Downgrade Ladenburg Thalmann Buy → Neutral
2018-08-13 Ripresa ROTH Capital Neutral
2018-01-03 Iniziato Ladenburg Thalmann Buy
2017-09-27 Ripresa ROTH Capital Buy
2017-09-22 Iniziato Jefferies Buy
2017-09-11 Iniziato JMP Securities Mkt Outperform
Mostra tutto

Savara Inc Borsa (SVRA) Ultime notizie

pulisher
May 09, 2025

Wells Fargo & Company MN Has $182,000 Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

May 09, 2025
pulisher
May 09, 2025

Savara Inc (NASDAQ:SVRA) Shares Sold by MetLife Investment Management LLC - Defense World

May 09, 2025
pulisher
May 09, 2025

Analysts Set Savara Inc (NASDAQ:SVRA) Target Price at $8.83 - Defense World

May 09, 2025
pulisher
May 08, 2025

Barclays PLC Grows Stake in Savara Inc (NASDAQ:SVRA) - Defense World

May 08, 2025
pulisher
May 07, 2025

Metric Deep Dive: Understanding Savara Inc (SVRA) Through its Ratios - DWinneX

May 07, 2025
pulisher
May 07, 2025

Raymond James Financial Inc. Buys Shares of 259,798 Savara Inc (NASDAQ:SVRA) - Defense World

May 07, 2025
pulisher
May 05, 2025

Savara Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 02, 2025

A stock that deserves closer examination: Savara Inc (SVRA) - uspostnews.com

May 02, 2025
pulisher
May 01, 2025

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference - Business Wire

May 01, 2025
pulisher
May 01, 2025

Legal & General Group Plc Sells 12,613 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

May 01, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 24, 2025

Savara Inc (NASDAQ:SVRA) Shares Purchased by Geode Capital Management LLC - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

JMP maintains $10 target on Savara stock post-BLA submission By Investing.com - Investing.com Nigeria

Apr 23, 2025
pulisher
Apr 23, 2025

Examining Savara Inc (SVRA) more closely is necessary - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

JMP maintains $10 target on Savara stock post-BLA submission - Investing.com

Apr 23, 2025
pulisher
Apr 21, 2025

Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA) - Seeking Alpha

Apr 21, 2025
pulisher
Apr 20, 2025

Savara Inc. Announces Equity Awards for New Employees - MSN

Apr 20, 2025
pulisher
Apr 20, 2025

JPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World

Apr 20, 2025
pulisher
Apr 15, 2025

Savara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Corebridge Financial Inc. Sells 4,330 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Savara Announces New Employment Inducement Grant | SVRA Stock Ne - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Savara Announces New Employment Inducement Grant - Enidnews.com

Apr 11, 2025
pulisher
Apr 11, 2025

Savara's Bold Move: 190K Share Grant Signals Aggressive Growth Strategy - Stock Titan

Apr 11, 2025
pulisher
Apr 11, 2025

Savara Inc (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN

Apr 10, 2025
pulisher
Apr 07, 2025

Savara to present aPAP treatment study at medical congresses By Investing.com - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

Savara to present aPAP treatment study at medical congresses - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management - Stock Titan

Apr 07, 2025
pulisher
Apr 06, 2025

259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc. - Defense World

Apr 06, 2025
pulisher
Apr 06, 2025

Raymond James Financial Inc. Invests $798,000 in Savara Inc (NASDAQ:SVRA) - The AM Reporter

Apr 06, 2025
pulisher
Apr 04, 2025

Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN

Apr 04, 2025
pulisher
Apr 03, 2025

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st

Apr 03, 2025
pulisher
Apr 02, 2025

Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - marketscreener.com

Apr 02, 2025
pulisher
Apr 01, 2025

Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - marketscreener.com

Apr 01, 2025
pulisher
Apr 01, 2025

Savara director David Ramsay acquires $416,250 in common stock - Investing.com India

Apr 01, 2025
pulisher
Mar 31, 2025

Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com South Africa

Mar 31, 2025

Savara Inc Azioni (SVRA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
Capitalizzazione:     |  Volume (24 ore):